currenttrendsindrugmetabolismandpharmacokinetics
文献类型：期刊论文
| 作者 | Liu Dongyang3; Hou Xiangyu1; Tang Lan2; Wang Xin4; Lyu Yuanfeng5; Chen Xiaoyan1 ; Liu Kexin6; Yu Aiming7; Zuo Zhong5; Bi Huichang8
|
| 刊名 | actapharmaceuticasinicab
 |
| 出版日期 | 2019 |
| 卷号 | 9期号:6页码:1113 |
| 关键词 | ARYL-HYDROCARBON RECEPTOR BLOOD-BRAIN-BARRIER ORGANIC ANION TRANSPORTERS CHRONIC KIDNEY-DISEASE PREGNANE-X-RECEPTOR P-GLYCOPROTEIN QUANTITATIVE PREDICTION CYTOCHROME-P450 ENZYMES DOWN-REGULATION IN-VIVO Pharmacokinetics Drug metabolism Drug-drug interactions Modeling Metabolizing enzymes Transporters Nuclear receptors Noncoding RNAs |
| ISSN号 | 2211-3835 |
| DOI | 10.1016/j.apsb.2019.10.001 |
| 英文摘要 | Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion (ADME) processes of a drug. Understanding PK properties is essential for drug development and precision medication. In this review we provided an overview of recent research on PK with focus on the following aspects: (1) an update on drug-metabolizing enzymes and transporters in the determination of PK, as well as advances in xenobiotic receptors and noncoding RNAs (ncRNAs) in the modulation of PK, providing new understanding of the transcriptional and posttranscriptional regulatory mechanisms that result in inter-individual variations in pharmacotherapy; (2) current status and trends in assessing drug-drug interactions, especially interactions between drugs and herbs, between drugs and therapeutic biologics, and microbiota-mediated interactions; (3) advances in understanding the effects of diseases on PK, particularly changes in metabolizing enzymes and transporters with disease progression; (4) trends in mathematical modeling including physiologically-based PK modeling and novel animal models such as CRISPR/Cas9-based animal models for DMPK studies; (5) emerging non-classical xenobiotic metabolic pathways and the involvement of novel metabolic enzymes, especially non-P450s. Existing challenges and perspectives on future directions are discussed, and may stimulate the development of new research models, technologies, and strategies towards the development of better drugs and improved clinical practice. (C) 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. |
| 资助项目 | [National Natural Science Foundation of China] ; [National Key Research and Development Program (China)] ; [111 project (China)] ; [Key Laboratory Foundation of Guangdong Province (China)] ; [Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (China)] ; [National Engineering and Technology Research Center for New drug Druggability Evaluation (Seed Program of Guangdong Province, China)] ; [Natural Science Foundation of Guangdong (China)] ; [National Institutes of Health (USA)] |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/280739]  |
| 专题 | 中国科学院上海药物研究所 |
| 作者单位 | 1.中国科学院上海药物研究所 2.南方医科大学 3.北京大学 4.华东师范大学 5.香港中文大学 6.大连医科大学 7.UC Davis School of Medicine 8.中山大学 |
| 推荐引用方式 GB/T 7714 | Liu Dongyang,Hou Xiangyu,Tang Lan,et al. currenttrendsindrugmetabolismandpharmacokinetics[J]. actapharmaceuticasinicab,2019,9(6):1113. |
| APA | Liu Dongyang.,Hou Xiangyu.,Tang Lan.,Wang Xin.,Lyu Yuanfeng.,...&Yang Mengbi.(2019).currenttrendsindrugmetabolismandpharmacokinetics.actapharmaceuticasinicab,9(6),1113. |
| MLA | Liu Dongyang,et al."currenttrendsindrugmetabolismandpharmacokinetics".actapharmaceuticasinicab 9.6(2019):1113. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。